

Sterol 3 β -glucosyltransferase biocatalysts with a range of selectivities, including selectivity for testosterone

Vatsala Malik,^a Meng Zhang,^a Lynn G. Dover,^a Julian S. Northen,^b Anthony Flinn,^b Justin J. Perry^a and Gary W. Black^{*a}

Cite this: *Mol. BioSyst.*, 2013, **9**, 2816

Received 23rd July 2013,
Accepted 29th August 2013

DOI: 10.1039/c3mb70303g

www.rsc.org/molecularbiosystems

The main objectives of this work were to characterise a range of purified recombinant sterol 3 β -glucosyltransferases and show that rational sampling of the diversity that exists within sterol 3 β -glucosyltransferase sequence space can result in a range of enzyme selectivities. In our study the catalytically active domain of the *Saccharomyces cerevisiae* 3 β -glucosyltransferase was used to mine putative sterol 3 β -glucosyltransferases from the databases. Selected diverse sequences were expressed in and purified from *Escherichia coli* and shown to have different selectivities for the 3 β -hydroxysteroids ergosterol and cholesterol. Surprisingly, three enzymes were also selective for testosterone, a 17 β -hydroxysteroid. This study therefore reports for the first time sterol 3 β -glucosyltransferases with selectivity for both 3 β - and 17 β -hydroxysteroids and is also the first report of recombinant 3 β -glucosyltransferases with selectivity for steroids with a hydroxyl group at positions other than C-3. These enzymes could therefore find utility in the pharmaceutical industry for the green synthesis of a range of glycosylated compounds of medicinal interest.

Introduction

Many lead compounds under development by the pharmaceutical industry are poorly water soluble and hence have non-ideal pharmacokinetic properties. One strategy, to overcome this problem is to link the drug substance to a water soluble moiety such as a carbohydrate, as the drug can be cleaved from this adduct by normal metabolic processes, ideally at the desired site of action. For example, the oral pro-drug testosterone-glucoside is currently under investigation by ProStrakan as an alternative to testosterone for patients suffering from hypogonadism.¹ Glycosidic derivatives are also of interest because they are commonly encountered in the *in vivo* metabolism of xenobiotic compounds as more water soluble products more suitable for excretion. Consequently, synthesis of appropriate carbohydrate derivatives might be employed to provide either more effective medicinal compounds or as a means to investigate drug pharmacokinetics through adsorption, distribution, metabolism and excretion (ADME) of a drug substance.²

Chemical methods of glycosylation are challenging and usually require a laborious protection-deprotection strategy which drives down overall chemical yield especially with complex aglycones.^{3,4} In addition, this approach proves industrially unattractive due to

the formation of intractable mixtures of side-products.^{3,4} In contrast, the chemo- and regioselective glycosylation of hydroxyl functionality is a common biotransformation and several glycosyltransferase (GTase) biocatalysts that perform efficient and selective conversions have been characterised.⁵ The majority of characterised GTases catalyze the transfer of the monosaccharide units from an activated nucleotide donor, such as a uridine diphosphate sugar, to specific acceptor molecules, during the formation of a glycosidic bond.⁶

Glucosylation of steroids with a hydroxyl group at the C-3 position is a common biotransformation catalyzed by GTases known as sterol 3 β -glucosyltransferases (systematic name, uridine diphosphate-glucose:sterol 3-O- β -D-glucosyltransferases; abbreviation, UDPG-SGTases; EC number, 2.4.1.173). UDPG-SGTase are members of GTase family 1 (GT1) of the Carbohydrate Active Enzymes database; a database that classifies enzymes that degrade, modify, or create glycosidic bonds into distinct protein sequence homology-based families.⁷ Characterized examples of UDPG-SGTases include UGT51 from *Saccharomyces cerevisiae* and UGT51B1 from *Pichia pastoris*.⁸ UGT51 and UGT51B1 each contain a GT1 GT-like conserved domain (cd03784) and pleckstrin homology/GRAM conserved domains (cd13215 and cd13216) that are often involved in targeting proteins to the plasma membrane.⁹⁻¹¹ Warnecke *et al.*⁸ also showed, by successively deleting the N-terminus of UGT51, followed by *in vitro* analysis, that it is only the GT1 GT-like conserved domain that is responsible for UDPG-SGTase activity.

There are several reports of characterised UDPG-SGTases, but many of these were performed with crude homogenate,

^a Industrial Biotechnology Research Group, Department of Applied Sciences, Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, NE1 8ST, UK. E-mail: gary.black@northumbria.ac.uk

^b Onyx Scientific Limited, Sunderland, SR5 2TQ, UK



purified membrane or partially purified enzyme preparations that may have contained mixtures of UDPG-SGTases.¹² Unfortunately, there are only a few reports of characterised recombinant UDPG-SGTases.¹² Our work therefore aimed to characterise a range of recombinant UDPG-SGTase catalytic domains, identified *via* sequence similarity to that of UGT51. Additionally, we aimed to show that rational sampling of the diversity that exists within sequence space, *i.e.* the number of possible amino acid sequences that can generate a particular enzyme activity, results in a range of enzyme selectivities. We show that a range of selectivities, including specificity for testosterone, a 17 β -hydroxysteroid, were present among the six recombinant UDPG-SGTases that were characterised in this study.

Results and discussion

Identification of putative GT1 GT-like domains

Difficulties in producing and characterising GTases are well-documented and are associated with the presence of non-catalytic domains involved in membrane spanning¹³ or non-integral membrane associations, such as the pleckstrin homology/GRAM domains.^{9–11} Therefore the N-terminally truncated catalytic domains, comprising of only the GT1 GT-like domain of several UDPG-SGTases were expressed in *E. coli*. This was achieved by conducting a BLASTP search using the amino acid sequence of the shortest C-terminal domain of the *S. cerevisiae* UGT51 that encoded a catalytically active UDPG-SGTase.⁸ The BLASTP search revealed similarities with the previously characterised UDPG-SGTase, UGT51B1 from *P. pastoris*, and several uncharacterised protein products. Fig. 1 shows the ClustalW2 multiple sequence alignment (version 2.1) comparison of the deduced N-terminally truncated domains of the sequences selected from the BLASTP search. The catalytic UDPG-SGTase domain of the *S. cerevisiae* UGT51, UGT51', is comprised of a polypeptide of 475 amino acids.^{8,11} This domain has 61–64% identity to the C-terminal domains of the selected sequences: UGT51B1 of *P. pastoris* (termed UGT51B1'), A7KAK6 of *P. angusta* (termed A7KAK6'), A5DNB9 of *M. guilliermondii* (termed A5DNB9'), Q6BN88 of *D. hansenii* (termed Q6BN88') and Q6CUV2 of *K. lactis* (termed Q6CUV2'); with the selected proteins showing a good level of sequence space diversity, *i.e.* 58–66% identity amongst themselves. Gene fragments corresponding to deletions of 723, 747, 770, 1065, 1030 and 718 codons from the 5' end of the sequences encoding UGT51, UGT51B1, A7KAK6, A5DNB9, Q6BN88 and Q6CUV2, respectively, were amplified, cloned and expressed in *E. coli*. The N-terminal residues of these sequences showed low levels of sequence identity (between 18–35%).

Expression of putative UDPG-SGTases using a range of *E. coli* BL21(DE3) strains

The N-terminally hexa-histidine tagged protein products with a calculated molecular mass of 54.6 kDa for UGT51', 53.5 kDa for UGT51B1', 54.2 kDa for A7KAK6', 60.6 kDa for A5DNB9', 61.8 kDa for Q6BN88' and 55.9 kDa for Q6CUV2' were expressed in *E. coli* BL21(DE3) strains. In all cases the largest amount of soluble protein expression was achieved after 18 h of post-induction growth at 23 °C and no expression was observed







in the absence of induction with isopropyl-1-thio- β -D-galactopyranoside. In two cases, UGT51' and A5DNB9', low expression levels in *E. coli* BL21(DE3) were seen (data not shown). To maximise expression of these genes *E. coli* BL21(DE3) CodonPlus strains were transformed with the LIC-constructs encoding UGT51' and A5DNB9'. Following this, increase in recombinant protein expression levels was observed for A5DNB9' and UGT51' encoding plasmids transformed in *E. coli* BL21(DE3) CodonPlus (RP) and *E. coli* BL21(DE3) Codon Plus (RIPL), respectively (data not shown). All gene fragments encoded soluble protein products (with yields between 10–100 mg L⁻¹) were purified using immobilised metal ion (Ni²⁺) chromatography. Multiple non-redundant peptides were identified by peptide fragmentation fingerprinting of UGT51', UGT51B1', A7KAK6', A5DNB9', Q6BN88' and Q6CUV2'; confirming the identity of the purified proteins (data not shown).

Identification of UDPG-SGTases with different selectivities

Each of the six recombinant proteins was assayed for activity against the following steroidal acceptors: ergosterol, cholesterol, estrone, estradiol, androstenedione and testosterone (Table 1). UGT51' from *S. cerevisiae* was shown to be active against the 3 β -hydroxysteroids, cholesterol and ergosterol (Fig. 2A and B, respectively); confirming the results seen by Warnecke *et al.*⁸ and revealing that activity is also observed with a purified N-terminally hexa-histidine tagged version of the enzyme. UGT51B1' from *P. pastoris* was also active against the 3 β -hydroxysteroids (Fig. 2A and B); again confirming the results seen by Warnecke *et al.*⁸ and revealing that it is only the GT1 GT-like domain of the *P. pastoris* enzyme that is responsible for UDPG-SGTase activity. The N-terminally truncated previously uncharacterised enzyme, A7KAK6, from *P. angusta* was also shown to be active against the 3 β -hydroxysteroids (Fig. 2A and B); adding further support to the suggestion that it is only the GT1 GT-like domain of UDPG-SGTases that is responsible for activity. The N-terminally truncated previously uncharacterised enzyme, Q6CUV2, from *K. lactis* was shown to be active against cholesterol (Fig. 2A) but not against ergosterol (data not shown). Interestingly, UGT51', UGT51B1' and A7KAK6' were also shown to be active against the 17 β -hydroxysteroid, testosterone (Fig. 2C) and to our knowledge this is the first report of UDPG-SGTases with activity against both 3 β - and 17 β -hydroxyl steroids. In fact, any reports of UDPG-SGTases with specificity towards glucosylation of steroids at positions other than C-3 are limited and importantly none involving the characterisation of a recombinant enzyme have been reported. For example, Madina *et al.*¹⁴ have shown that a near to pure 27 β -hydroxy glucosyltransferase from the cytosolic fraction of the medicinal plant, *Withania somnifera*, showed activity against testosterone; Poppenberger *et al.*¹⁵ have shown that wild-type seedlings of *Arabidopsis* converted the brassinosteroid brassinolide to the 23-O-glucoside, but in the transgenic plants silenced in UGT73C5 expression no 23-O-glucoside was detected; and O'Reilly *et al.*¹⁶ have shown that a baculovirus ecdysteroid UDP-glucosyltransferase produces ecdysone 22-O- β -D-glucopyranoside.



Table 1 Chemical structures of steroids that were used in this study

Acceptor substrate	Structure
Ergosterol	
Cholesterol	
Estrone	
Estradiol	
Androstenedione	
Testosterone	

retention time of 1.4 min) were determined using authentic standards. Both were observed in the reaction mixture after 2 h (Fig. 3) but after an overnight incubation only the peak for the testosterone glucoside could be observed. This was also supported by TLC analysis of an overnight incubation with testosterone (data not shown) and was also the case for cholesterol and ergosterol overnight incubations (data not shown). An added advantage to this analytical method was that testosterone and the corresponding glucosylated compound were separated by a chromatographic method with a run time of 5 min at room temperature, an assay which compares favourably with previous studies where separation was achieved with longer retention times at elevated column temperatures.^{19,20}

Kinetic analysis of UDPG-SGTases

Kinetic analysis was performed for all active UDPG-SGTases using cholesterol and testosterone as acceptors and UDP-[¹⁴C] glucose as the donor. All reactions demonstrated classic Michaelis-Menten




Fig. 2 Thin layer chromatograms of extracted reaction products following 2 h incubations. Reaction products of UGT51B1', *P. pastoris* UDPG-SGTase; A7KAK6', *P. angusta* UDPG-SGTase; UGT51', *S. cerevisiae* UDPG-SGTase; Q6CUV2', *K. lactis* UDPG-SGTase using cholesterol (panel A), ergosterol (panel B) and testosterone (panel C) as acceptors. Lanes C, T and E are the cholesterol, testosterone and ergosterol controls, respectively, without enzyme. CG, TG and EG are cholesterol glucoside, testosterone glucoside and ergosterol glucoside, respectively.

kinetics with goodness-of-fit statistical analysis of the linear trend lines of the resulting Lineweaver-Burke plots producing R^2 values between 0.8052 to 0.9599 (data not shown). For enzymes active against cholesterol and testosterone, the binding capacity of the enzymes for cholesterol was higher (≥ 4.5 -fold) than that for testosterone (Table 2). Similarly, the reaction rate of the enzymes active against cholesterol was higher (≥ 1.8 -fold)



Table 3 Primer pairs used for PCR and *E. coli* (DE3) strains used for expression. LIC-specific ends are shown in bold

Source organism and UniProtKB accession number	Primer pairs	<i>E. coli</i> strain used for expression
<i>S. cerevisiae</i> Q06321	5'- caccaccaccacatg ATTGATGAGAATCCGCAC-3' 5'- gaggagaaggcgcg TTAAATCATCGTCCACCCTCA-3'	BL21(DE3) CodonPlus (RP) (Agilent Technologies, UK)
<i>P. pastoris</i> Q9Y751	5'- caccaccaccacatg AACCAGTATTCTACGTCAGA-3' 5'- gaggagaaggcgcg TTACACTTCAAACCATGATC-3'	BL21(DE3) CodonPlus (RIPL) (Agilent Technologies, UK)
<i>M. guilliermondii</i> A5DNB9	5'- caccaccaccacatg TTAGAAGATTCACCACACTCATC-3' 5'- gaggagaaggcgcg TTAGTCGTTAGTTGTCGTTG-3'	BL21(DE3) CodonPlus (RP) (Agilent Technologies, UK)
<i>P. angusta</i> A7KAK6	5'- caccaccaccacatg ATAGAAGAGCATCCATTGACC-3' 5'- gaggagaaggcgcg TTAAACCAGTAACCACGAGCC-3'	BL21(DE3) (Merck Chemicals, UK)
<i>K. lactis</i> Q6CUV2	5'- caccaccaccacatg GTTGAAAAAACCCGTATT-3' 5'- gaggagaaggcgcg TTATATCAGAAGCCAGGATC-3'	BL21(DE3) (Merck Chemicals, UK)
<i>D. hansenii</i> Q6BN88	5'- caccaccaccacatg TTAGAAGATTCTCCATTCTAT-3' 5'- gaggagaaggcgcg TTATTGTTAGCATCTGTAAC-3'	BL21(DE3) (Merck Chemicals, UK)

of the enzymes in this study (data not shown) which is in agreement with that of the Madina *et al.*¹⁴ who have reported that the presence of Mn²⁺ ions did not affect the activity of the plant 3 β -glucosyltransferase.

Conclusions

We have shown that the approach of rational sampling of the diversity that exists within sequence space identified *via* a BLAST search generated a range of UDPG-SGTases with the same activity but different selectivity. We suggest that this class of enzyme could become valuable biocatalysts in the pharmaceutical industry (and fine chemical industry) due to their ability to glycosylate a range of sterols without the need to use protection-deprotection strategies.

Experimental

Yeast strains and propagation

Saccharomyces cerevisiae (ATCC 204508) and *Pichia pastoris* (ATCC 201178) were obtained from the LGC Standards (UK). *Pichia angusta* (DSM 70277), *Meyerozyma guilliermondii* (DSM 6381) and *Kluyveromyces lactis* (DSM 70799) were obtained from DSMZ (Germany). *Debaryomyces hansenii* (CBS 767) was obtained from the CBS Fungal Biodiversity Centre (Netherlands). *S. cerevisiae* and *P. pastoris* were grown overnight at 30 °C, 100 rpm in yeast extract peptone dextrose medium (2% [w/v] Bacto Peptone [BD, UK], 1% [w/v] yeast extract [Oxoid, UK], 2% [w/v] glucose [Sigma, UK]) whereas the other strains were grown overnight at 25 °C, 100 rpm in yeast extract-malt extract medium (0.3% [w/v] yeast extract [Oxoid, UK], 0.3% [w/v] malt extract [Oxoid, UK], 0.5% peptone [Oxoid, UK], 1% [w/v] glucose [Sigma, UK]).

Identification and cloning of UDPG-SGTase encoding genes

A BLASTP (version 2.2.27)²² search of the databases was conducted using UGT51' (residues 724 to 1198 of UGT51) as a query to identify similar sequences. Gene sequences encoding N-terminal truncated versions of the proteins identified were

selected *via* rationally sampling the diversity that exists within sequence space. The selected genes (Table 3 for UniProtKB accession numbers) were then cloned and expressed in *Escherichia coli*. Genomic DNA was prepared from overnight cultures using the DNeasy Blood and Tissue Kit [Qiagen, UK] and the primer pairs [Eurofins MWG Operon, Germany], shown in Table 3, were used to amplify the gene fragments *via* PCR using KOD Hot Start DNA Polymerase [Merck Chemicals, UK]. PCR was performed for 5 cycles at an annealing temperature of 50 °C then for 25 cycles at an annealing temperature of 73 °C. The amplified products were inserted into pET-YSBLIC (kindly provided by Dr Mark Fogg of the York Structural Biology Laboratory, York University, UK) *via* ligation independent cloning, as described by Bonsor *et al.*²³

Protein expression, purification and identification

Recombinant proteins were expressed from different *E. coli* BL21(DE3) strains as indicated in Table 3. Cells were grown at 37 °C with shaking at 200 rpm in 1 L LB medium supplemented with 100 $\mu\text{g mL}^{-1}$ kanamycin for LIC-constructs transformed in *E. coli* BL21(DE3) and 100 $\mu\text{g mL}^{-1}$ kanamycin plus 34 $\mu\text{g mL}^{-1}$ chloramphenicol for LIC-constructs transformed in *E. coli* BL21(DE3) CodonPlus (RP/RIPL) to an absorbance of 0.6 at 600 nm. Induction was performed by the addition of isopropyl-1-thio- β -D-galactopyranoside, to a concentration of 240 $\mu\text{g mL}^{-1}$, followed by further incubation for 3 h and 18 h at 23 °C, 30 °C and 37 °C, 100 rpm. Cells were harvested by centrifugation (15 min, 4000 $\times g$, 4 °C), resuspended in 5 mL of 50 mM Na₂HPO₄-HCl, 0.5 M NaCl, 10 mM imidazole, pH 7.4 followed by cell disruption by sonication (6 \times 10 s at 14 microns). N-terminally hexahistidine tagged protein products were purified *via* immobilised metal ion (Ni²⁺) chromatography (GE Healthcare, UK) using a linear gradient of 10 to 500 mM imidazole. Protein concentration and buffer exchange into 5 mM Tris-HCl (pH 8.0) of the purified proteins was achieved using 30 kDa cut-off concentrator units [Vivaproducts, USA]. The purity of UDPG-SGTases was judged by SDS-PAGE and Coomassie blue staining.²⁴ Peptide fragmentation fingerprinting of purified proteins was used to



confirm the identity of the protein according to the methods and criteria of Yang *et al.*²⁵

UDPG-SGTase activity analysis

The purified enzymes were tested for selectivity using ergosterol [Sigma-Aldrich, UK], cholesterol [Sigma-Aldrich, UK], estrone [Sigma-Aldrich, UK], estradiol [Sigma-Aldrich, UK], androstenedione [TCI, UK] and testosterone [Sigma-Aldrich, UK] as steroidal acceptor substrates (Table 1 for chemical structures of these steroids). In addition, β -naphthol, [Sigma-Aldrich, UK] was used as a non-steroidal aromatic acceptor substrate. All acceptor stock solutions were prepared in 100% (v/v) ethanol. For TLC/LC-MS analysis, the assay mixture contained (in a total volume of 100 μ L) the following: 400 μ M acceptor, 360 μ M UDP-glucose [Sigma-Aldrich, UK] or UDP-galactose [Sigma-Aldrich, UK], 50 μ M MnCl_2 [Sigma-Aldrich, UK] when appropriate, 2 μ g purified enzyme and 10 mM $\text{Na}_2\text{HPO}_4\text{-HCl}$, pH 7.8. The assays were performed in triplicate and terminated after 2 h incubation at 30 $^\circ\text{C}$. The identity of the testosterone glucoside was confirmed by comparison with an authentic standard kindly provided by ProStrakan Group Plc, UK. Assays for TLC analysis were terminated by the addition of 0.9 mL of 0.45% (w/v) NaCl and 4 mL of chloroform-methanol (2:1, v/v), 2 μ L separated on silica gel 60 TLC plates [Merck Chemicals, UK] according to the procedure described in Warnecke *et al.*⁸ and visualised by spraying with 15% (w/v) phosphotungstic acid followed by charring using a heat gun. Assays for LC-MS analysis were only performed with testosterone and were terminated by the addition of 100 μ L of 0.3 M HCl, then diluted with 800 μ L of 18.2 M Ω cm^{-1} water and 20 μ L applied to a Phenomenex Luna 5 μ m CN column (5.0 cm \times 2 mm). Isocratic reverse phase separation was achieved in 5 min with a flow rate of 150 μ L min^{-1} of 30% (v/v) acetonitrile, 1% (v/v) acetic acid mobile phase and the analytes detected using a ThermoFinnigan LCQ Advantage ion-trap mass-spectrometer in selected ion monitoring mode with a spray voltage of 4.5 kV, capillary voltage of 5 V and capillary temperature of 230 $^\circ\text{C}$. For kinetic analysis, the assay mixture contained (in a total volume of 75 μ L) the following: acceptor (cholesterol or testosterone) ranging from 12.5–200 μ M, 50 000 dpm UDP-[^{14}C] glucose (final concentration 0.88 μ M, specific activity 302 mCi mmol^{-1} , Perkin Elmer, UK), 0.5 μ g purified enzyme diluted in 10 mM $\text{Na}_2\text{HPO}_4\text{-HCl}$, pH 7.8. After incubation for 20 min at 30 $^\circ\text{C}$, the reaction was terminated by the addition of 125 μ L 0.45% (w/v) NaCl followed by extraction using 300 μ L of water-saturated ethyl acetate. For each sample, 150 μ L of the organic layer was counted for 3 min by liquid scintillation counting using the Tricarb 2200 CA (Perkin Elmer, UK).

Acknowledgements

We would like to thank Edwin Ludkin for technical help with LC-MS.

References

- 1 ProStrakan, R&D, in <http://www.prostrakan.nl/rd.htm>, 2013.
- 2 E. S. Hansen, S. A. Osmani, C. Kristensen, B. L. Moller and J. Hansen, *Phytochemistry*, 2009, **70**, 473–482.
- 3 D. E. Robertson and B. A. Steer, *Curr. Opin. Chem. Biol.*, 2004, **8**, 141–149.
- 4 M. M. Palcic, *Curr. Opin. Biotechnol.*, 1999, **10**, 616–624.
- 5 S. Rabbani, O. Schwardt and B. Ernst, *Chimia*, 2006, **60**, 23–27.
- 6 K. Hashimoto, T. Tokimatsu, S. Kawano, A. C. Yoshizawa, S. Okuda, S. Goto and M. Kanehisa, *Carbohydr. Res.*, 2009, **344**, 881–887.
- 7 B. L. Cantarel, P. M. Coutinho, C. Rancurel, T. Bernard, V. Lombard and B. Henrissat, *Nucleic Acids Res.*, 2009, **37**, D233–D238.
- 8 D. Warnecke, R. Erdmann, A. Fahl, B. Hube, F. Muller, T. Zank, U. Zahringer and E. Heinz, *J. Biol. Chem.*, 1999, **274**, 13048–13059.
- 9 M. A. Lemmon, *Cell*, 2005, **120**, 574–576.
- 10 T. Doerks, M. Strauss, M. Brendel and P. Bork, *Trends Biochem. Sci.*, 2000, **25**, 483–485.
- 11 M. Oku, D. Warnecke, T. Noda, F. Muller, E. Heinz, H. Mukaiyama, N. Kato and Y. Sakai, *EMBO J.*, 2003, **22**, 3231–3241.
- 12 S. Grille, A. Zaslowski, S. Thiele, J. Plat and D. Warnecke, *Prog. Lipid Res.*, 2010, **49**, 262–288.
- 13 P. M. Coutinho, E. Deleury, G. D. Davies and B. Henrissat, *J. Mol. Biol.*, 2003, **328**, 307–317.
- 14 B. R. Madina, L. K. Sharma, P. Chaturvedi, R. S. Sangwan and R. Tuli, *Biochim. Biophys. Acta, Proteins Proteomics*, 2007, **1774**, 392–402.
- 15 B. Poppenberger, S. Fujioka, K. Soeno, G. L. George, F. E. Vaistij, S. Hiranuma, H. Seto, S. Takatsuto, G. Adam, S. Yoshida and D. Bowles, *Proc. Natl. Acad. Sci. U. S. A.*, 2005, **102**, 15253–15258.
- 16 D. R. O'Reilly, O. W. Howarth, H. H. Rees and L. K. Miller, *Insect Biochem.*, 1991, **21**, 795–801.
- 17 A. R. Bellu and J. A. K. W. Kiel, *Microsc. Res. Tech.*, 2003, **61**, 161–170.
- 18 C. A. G. M. Weijers, M. C. R. Franssen and G. M. Visser, *Biotechnol. Adv.*, 2008, **26**, 436–456.
- 19 X. F. Li, M. S. Ma, A. Cheng, J. Zheng and Y. K. Tam, *Anal. Chim. Acta*, 2002, **457**, 165–171.
- 20 C. J. Zea and N. L. Pohl, *Anal. Biochem.*, 2004, **328**, 196–202.
- 21 B. R. Madina, L. K. Sharma, P. Chaturvedi, R. S. Sangwan and R. Tuli, *Biochim. Biophys. Acta, Proteins Proteomics*, 2007, **1774**, 1199–1207.
- 22 S. F. Altschul, T. L. Madden, A. A. Schäffer, Z. Z. Zhang, W. Miller and D. Lipman, *Nucleic Acids Res.*, 1997, **25**, 3389–3402.
- 23 D. Bonsor, S. F. Butz, J. Solomons, S. Grant, I. J. S. Fairlamb, M. J. Fogg and G. Grogan, *Org. Biomol. Chem.*, 2006, **4**, 1252–1260.
- 24 U. K. Laemmli, *Nature*, 1970, **227**, 680–685.
- 25 Q. Yang, M. Zhang, D. J. Harrington, G. W. Black and I. C. Sutcliffe, *Microbes Infect.*, 2011, **13**, 757–760.

